Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 31, 2023

SELL
$35.27 - $42.24 $11,991 - $14,361
-340 Reduced 3.06%
10,775 $380 Million
Q2 2023

Aug 11, 2023

BUY
$37.4 - $42.94 $415,701 - $477,278
11,115 New
11,115 $422 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $14.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Genus Capital Management Inc. Portfolio

Follow Genus Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Genus Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Genus Capital Management Inc. with notifications on news.